Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia
21/07/2026 09:49
BRIEF-Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia July 21 (Reuters) - Kyowa Kirin Co Ltd 4151.T:
EUROPEAN COMMISSION APPROVES CRYSVITA® (BUROSUMAB) FOR INFANTS WITH X-LINKED HYPOPHOSPHATAEMIA IN THE EUROPEAN UNION
KYOWA KIRIN CO - CRYSVITA GRANTED TWO-YEAR EXTENSION OF ORPHAN MARKET EXCLUSIVITY IN EU TO FEBRUARY 2030
Source text: ID:nBw8trhyma
Further company coverage: 4151.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia